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Abstract
Background: To observe mRNA expression of tumor-specific antigen MAGE, BAGE and GAGE in epithelial ovarian 
cancer tissues and cell lines, to explore the relationship between gene expression and diagnosis, treatment and 
prognosis of ovarian cancer, and to evaluate the feasibility of their gene products as markers, and an immunotherapy 
target for ovarian cancer.
Methods: mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE were determined by reverse transcription 
polymerase chain reaction (RT-PCR) in 14 cases of normal ovarian tissue, 20 cases of ovarian benign tumor specimens, 
41 cases of ovarian cancer specimens, and ovarian cancer cell lines SKOV3, A2780, and COC1.
Results: MAGE, GAGE and BAGE genes were not expressed in normal ovarian tissue. In benign tumors, only the MAGE 
gene was expressed; the expression rate of this gene in benign tumors was 15% (3/20). In ovarian cancer tissues, 
MAGE-1 and MAGE-3 was highly expressed, with expression rates of 53.7% (22/41) and 36.6% (15/41), while GAGE-1/2 
and BAGE had relatively low expression, with rates of 26.8% (11/41) and 14.6% (6/41). In metastatic lesions of ovarian 
cancer, only MAGE-1 and BAGE were expressed, with expression rates of 28.6% (2/7) and 14.3% (1/7). The positive 
expression rates of MAGE-1 and MAGE-3 in serous cystadenocarcinoma were significantly higher than that in other 
types of ovarian cancer (P < 0.05). Gene expression rate was not correlated with menopause or lymph node metastasis. 
Positive expression of MAGE-1 and MAGE-3 was positively correlated with tumor differentiation and the clinical stage of 
the ovarian cancer. In addition, the positive expression rate of BAGE was significantly higher in ovarian cancer patients 
with ascites (P < 0.05). The mRNA expression profiles of MAGE, GAGE and BAGE in ovarian carcinoma cell lines SKOV3, 
A2780 and COC1 varied, but there was at least one gene expressed in each cell line.
Conclusion: Tumor-specific antigen MAGE, BAGE and GAGE may play a role in the occurrence and development of 
ovarian cancer. These genes can be used as one of the important indicators for early diagnosis, efficacy evaluation and 
prognostic determination of ovarian cancer.
Background
Cancer-testis antigen (CTA), a type of protein restric-
tively expressed in the testes and malignant tumors, is
considered to be associated with the cell carcinogenesis.
Hence, CT A is thought to be an ideal target for cancer
immunotherapy and has gained extensive attention in
these years [1]. MAGE, GAGE and BAGE family genes,
all of which are members of CTA, are expressed not only
in melanoma cells, but also in many tumor tissues. More-
over, their expression is closely related to the occurrence,
development and prognosis of cancer. The antigens
encoded by these genes can be recognized by the body's
immune cells and can then induce the body to produce
specific humoral and cellular immunity. It has been
reported that MAGE, GAGE, and BAGE genes, as well as
their products, could be used for molecular diagnosis and
immunotherapy of tumors [2]. In recent years, the diag-
nosis and treatment of ovarian cancers have improved,
but the long-term survival rate, especially the survival
rate for advanced cases, still has not been markedly
increased. Therefore, it is very important to search for
tumor-specific antigen (TSA) and tumor-associated anti-
gen (TAA) to ensure the early detection, early diagnosis
and early treatment of ovarian cancer. Domestic and
international scholars have conducted a great deal of
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research on the gene expression profiles, functions and
mechanisms of MAGE, BAGE and GAGE. However,
research on the role of these genes in ovarian cancer has
been sparse. In the present work, the mRNA expression
of MAGE-1, MAGE-3, GAGE-1/2 and BAGE was ana-
lyzed by reverse transcription polymerase chain reaction
(RT-PCR), and the feasibility of their gene products as




Ovarian cancer cell lines SKOV3, A2780 and COC1 were
established in China. SKOV3, COC1 and normal ovarian
epithelial cells (NOEC) were provided by the Bioengi-
neering Center of Qilu Hospital, Shandong University.
Melanoma cell lines MEL526, a positive control, were
kindly given by Dr. Takesako. Cells were cultured in
RPMI 1640 culture medium (containing 10% fetal calf
serum, 100 u/ml penicillin and 100 u/ml streptomycin) at
37°C with 5% CO2. The cells were collected by conven-
tional digestion and stored at -80°C when they reached
about 80% confluence.
2. Clinical data and tissue samples
Patients who visited the Gynecology service of Qilu Hos-
pital, Shandong University between January 2005 and
December 2008 were selected. The tissue samples were
obtained at the time of surgery in the Department of
Gynecology, Qilu Hospital, Shandong University. The
present study was approved by the ethics committee of
the Shandong University. All samples were obtained with
medical-ethics approval and all patients gave informed
consent. There were 14 cases of normal ovarian tissues,
20 cases of ovarian benign tumor samples, 41 cases of
ovarian cancer samples and 7 cases of metastatic lesions
of ovarian cancer samples. The obtained tissues were
confirmed by histopathological examination and stored
in liquid nitrogen at 10 min after surgery. The patients'
clinical data were recorded in detail. Tumor histological
grades and clinical stages were evaluated according to the
pathological results after surgery. The clinical stages of
ovarian cancer were based on FIGO (presented in 2000)
staging criteria. Of the 41 cases of ovarian cancer, there
were 18 cases with serous cystadenocarcinoma, 13 cases
with mucinous cystadenocarcinoma, 6 cases with endo-
metrial carcinoma, and 4 cases with clear cell tumors.
There were 5 cases in Stage I, 9 cases in Stage II, 23 cases
in Stages III and 4 cases in Stage IV. With regards to his-
tological grading, 6 cases were in G1, 18 cases were in G2
and 17 cases were in G3. There were 15 patients with
ascites and 26 patients without ascites. Lymph node
m e t a s t a s i s  o c c u r r e d  i n  1 5  c a s e s .  T h e  p a t i e n t s  a g e d
between 23 and 65 years, with an average age of 45.2
years.
3. Determination of mRNA expression of MAGE-1, MAGE-3, 
GAGE-1/2 and BAGE gene
Total RNA was extracted with Trizol (Shanghai Bio-Engi-
neering Company) from various cell lines and tissue sam-
ples. A260 and A280 of total RNA were measured by UV-
spectrophotometer. To synthesize the first strand of
CDNA, 4 μg of RNA was reverse-transcribed with the
reverse transcriptase M-MLV using Oligo dT (Shanghai
Bio-Engineering Company) as the downstream primer.
PCR primers were designed on different exons to ensure
the specificity of amplification and to avoid genomic DNA
contamination. The primers are listed in Table 1.
The PCR program was as follows. MAGE-1 and β-actin:
35 cycles of denaturation at 94°C for 45 sec, annealing at
55°C for 45 sec and extension at 72°C for 1 min; MAGE-3:
40 cycles of denaturation at 94°C for 1 min, annealing at
66°C for 1 min 15 sec and extension at 72°C for 1 min;
GAGE-1,2: 30 cycles of denaturation at 94°C for 1 min,
annealing at 56°C for 2 min and extension at 72°C for 3
min; and BAGE: 30 cycles of denaturation at 94°C for 1
min, annealing at 60°C for 2 min and extension at 72°C for
2 min. The PCR program was started with pre-denatur-
ation at 94°C for 5 min and ended with a final 72°C exten-
sion for 5 min. The PCR products were separated by
electrophoresis on a 1.5% agarose gel, stained with ethid-
ium bromide and observed with UV lamp. Results were
determined by quantification with a JD801 Image Analysis
system 3.3 (JiangSu JEDA Science-Technology Develop-
ment Co., Ltd, Nanjing). The melanoma cell lines MEL526
were a positive control, the sample without M-MLV
reverse transcriptase was a negative control, and β-actin
was an internal control for the RT-PCR. According to the
sequences in GenBank, the length of PCR products for
Table 1: Primers for MAGE, GAGE and BAGE.
Gene Primer Sequence
MAGE-1 P1 5'-ACT ACC TTC ACT CG-3'
P2 5'-CTC CCA TCA TAC ACC TCC-3'
MAGE-3 P1 5'-TGG AGG ACC AGA GGC CCC C-3'
P2 5'-GGA CGA TTA TCA GGA GGC CTG C-3'
GAGE-1/2 P1 5'-GAC CAA GAC GCT ACG TAG-3'
P2 5'-CCA TCA GGA CCA TCT TCA-3'
BAGE P1 5'-TGG CTC GTC TCA CTC TGG-3'
P2 5'-CCT CCT ATT GCT CCT GTT G-3'
β-actin P1 5'-AGC GAG CAT CCC CCA AAG TT-3'
P2 5'-GGG CAC GAA GGC TCA TCA TT-3'Zhang et al. BMC Cancer 2010, 10:163
http://www.biomedcentral.com/1471-2407/10/163
Page 3 of 6
MAGE-1, MAGE-3, GAGE-1/2 and BAGE genes were 485
bp, 724 bp, 243 bp and 284 bp, respectively.
4. Statistical analysis
All analyses were performed with SPSS 10.0 software.
The measurement data were analyzed with the t-test,
while the comparison of menopause, pathological fea-
tures (such as tumor histological type and clinical stage)
and gene expression were analyzed with the χ2 test. Statis-
tical differences were defined as P < 0.05.
Results
1. mRNA expression of MAGE, GAGE and BAGE in ovarian 
cancer cell lines
The mRNA expression profiles of MAGE, GAGE and
BAGE in ovarian carcinoma cell lines SKOV3, A2780 and
COC1 were varied, but there was at least one gene
expressed in each cell line. In SKOV3 (Figure 1), MAGE-1
was expressed (line 2, a band ranging between 400-500
bp). In A2780 (Figure 2), MAGE-1 (line 2, a band ranging
between 400-500 bp), MAGE-3 (line 3, a band ranging
between 700-800 bp) and GAGE-1/2 (line 5, a band rang-
ing between 200-300 bp) were expressed. In COC1 (Fig-
ure 3), MAGE (line 2, a band ranging between 400-500
bp) and MAGE-3 (line 3, a band ranging between 700-
800 bp) were expressed.
2. mRNA expression of MAGE, GAGE and BAGE in various 
ovarian tissues
MAGE, GAGE and BAGE genes were not expressed in
normal ovarian tissue. In benign tumors, only the MAGE
gene was expressed, and the positive rate was 15% (3/20).
In ovarian cancer tissues, MAGE-1 and MAGE-3 were
highly expressed with expression rates of 53.7% (22/41)
and 36.6% (15/41), while GAGE-1/2 and BAGE had rela-
tively low expression rates of 26.8% (11/41) and 14.6% (6/
41). In metastatic lesions of ovarian cancer, only MAGE-1
and BAGE were expressed with expression rates of 28.6%
(2/7) and 14.3% (1/7) (Table 2 & Figure 4).
3. The relationship between the pathological types of 
ovarian cancer and the positive expression rates of MAGE, 
GAGE and BAGE
In serous cystadenocarcinoma samples, the positive
expression rates of MAGE-1 and MAGE-3 were 77.8%
(14/18) and 66.7% (12/18), which were significantly
higher than that in other types of ovarian cancer (P <
0.05). Although the expression of GAGE-1/2 and BAGE
was low in ovarian cancer tissues, their positive expres-
sion rates were relatively high in serous cystadenocarci-
nomas (Table 3).
4. The correlation between the pathological features of 
ovarian cancer and the positive expression rates of MAGE, 
GAGE and BAGE
Clinical data of ovarian cancer patients with or without
MAGE, GAGE or BAGE expression were analyzed. The
expression of MAGE, GAGE and BAGE was not corre-
lated with menopause or lymph node metastasis (P  >
0.05). Positive expression of MAGE-1 and MAGE-3 was
positively correlated with the pathological grade and clin-
ical stage of ovarian cancer patients (P < 0.05), while pos-
itive expression of MAGE-1 and MAGE-3 was not related
to pathological grade and clinical stage (P > 0.05). Addi-
tionally, ascites was correlated with the expression of
BAGE, as indicated by the fact that the positive expres-
Figure 1 mRNA expression profile of MAGE, BAGE and GAGE in 
SKOV3 cells. (1, 8: DL 2000 marker, 2: MAGE-1, 3: MAGE-3, 4: BAGE, 
5.GAGE-1/2, 6,7: negative control).
Figure 2 mRNA expression profile of MAGE, BAGE and GAGE in 
A2780 cells. (1, 8: DL 2000 marker, 2: MAGE-1, 3: MAGE-3, 4: BAGE, 
5.GAGE-1/2, 6,7: negative control).
Figure 3 mRNA expression profile of MAGE, BAGE and GAGE in 
COC1 cells. (1, 8: DL 2000 marker, 2: MAGE-1, 3: MAGE-3, 4: BAGE, 
5.GAGE-1/2, 6,7: negative control).Zhang et al. BMC Cancer 2010, 10:163
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sion rate of BAGE was significantly higher in ovarian can-
cer patients with ascites (P < 0.05) (Table 4).
Discussion and Conclusions
At present, 23 members have been found in the MAGE
gene family. They are located on the human X chromo-
some and are highly expressed in a variety of tumors. The
proteins encoded by these genes contain more than 300
amino acids, and peptides processed from these proteins
can bind to all types of human leukocyte antigens to form
complexes, which can be recognized by autologous T-
lymphocytes. The GAGE gene family contains at least
eight near-source genes, which are all located on the
human X chromosome. Antigen peptide YRPRPRRY
encoded by the GAGE-1 gene and GAGE-2 gene could
interact with HLA-Cw*0601 to form a complex, which
may be recognized by activated cytotoxic T-lymphocyte
[3]. In addition to the several BAGE-family members that
were found previously, another five new BAGE genes
have been discovered and are located adjacent to the cen-
tromere of chromosome 13 or 21. Additionally, there are
nine BAGE gene segments located adjacent to the cen-
tromere of chromosomes 9, 13, 18 or 21. These genes and
gene segments are highly homologous (90%-99%). Poly-
peptides encoded by BAGE genes contain 43 amino acids,
whose AARAVFLAL fragment interacts with HLA-
Cw*1601 and is then recognized by activated cytotoxic T
lymphocytes.
MAGE, BAGE, and GAGE proteins are processed to
peptides in cancer cells by low molecular weight polypep-
tide (LMP) and are then transported to the lumen of the
endoplasmic reticulum by transporter associated with
antigen processing (TAP). The antigen peptides interact
with MHC I molecules to form complexes, which are
expressed on the surface of tumor cells via the Golgi
apparatus. CTL can recognize the surface complexes
through T cell antigen receptor (TCR) interactions and
can destroy the tumor cells through a killing mechanism.
Therefore, MAGE, BAGE, and GAGE genes, as well as
their products have wide application prospects in tumor-
specific initiative immunotherapy [4].
Many tumor marker studies have shown that BAGE,
MAGE-1/3 and GAGE-1/2 are expressed in the majority
of different types of ovarian cancer, while not in the nor-
mal ovarian tissue or body fluids. Russo et al. [5] detected
transcription levels of MAGE-1 and MAGE-3 in 54
patients with epithelial ovarian cancer using the RT-PCR
method. Their results showed that the expression rates of
MAGE-1, MAGE-3, BAGE and GAGE were 28%, 17%,
15% and 31%, respectively. Moreover, they reported that
an increase in the expression rate of MAGE-1 was found
with the increase in tumor clinical stage, as indicated by
the fact that the expression rate of MAGE-1 in Stage III
and Stage IV of ovarian cancer was 22% and 43%, respec-
tively. Gillespie et al. [6] found that the expression rate of
MAGE-1 in ovarian cancer was 56%, while the expression
rates of MAGE-2, -3, -4, BAGE and GAGE were relatively
low. Hofmann et al. [3] obtained ascites samples obtained
by fine-needle aspiration and found that BAGE, MAGE-
1, MAGE-3 and GAGE-1/2 mRNA was positively
expressed in 56% (15/27), 7% (2/27), 30% (8/27) and 30%
(8/27) of samples, respectively. The sensitivity was 94%;
the specificity was 94%; and in one case, there was a false
positive when these genes were jointly detected in ascites
samples. Therefore, the detection of BAGE, GAGE, and
MAGE mRNA in ovarian cancer ascites may be a poten-
tial diagnostic option.
In our study, MAGE, GAGE and BAGE genes were not
expressed in normal ovarian tissue, only the MAGE-1
gene was expressed in benign tumors at a rate of 15% (3/
20). In ovarian cancer tissues, MAGE-1 and MAGE-3
Table 2: mRNA expression of MAGE, GAGE and BAGE in various ovarian cancer tissues [Cases(%)].
Tissue Cases (n) MAGE-1 MAGE-3 BAGE GAGE-1/2
Normal ovary 14 0 (0) 0 (0) 0 (0) 0 (0)
Ovarian benign tumor 20 3 (15) 0 (0) 0 (0) 0 (0)
Ovarian cancer 41 22 (53.7) 15 (36.6) 6 (14.6) 11 (26.8)
Metastatic lesions of 
ovarian cancer
7 2 (28.6) 0 (0) 1 (14.3) 0 (0)
Figure 4 mRNA expression profile of MAGE, BAGE and GAGE in 
ovarian cancer tissues. (1, 8: DL 2000 marker, 2: MAGE-1, 3: MAGE-3, 
4: BAGE, 5.GAGE-1/2, 6,7: negative control).Zhang et al. BMC Cancer 2010, 10:163
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genes were highly expressed with a positive rate of 53.7%
(22/41) and 36.6% (15/41), respectively. The expression
rate of the MAGE-1 gene was slightly lower than that
reported by Gillespie et al. [6]. The expression rates of the
GAGE-1/2 and BAGE genes in ovarian cancer were 26.8%
(11/41) and 14.6% (6/41), respectively, which were signifi-
cantly higher than that reported by Gillespie et al. [6]. In
cancer metastasis outside the ovary, only the MAGE-1
and BAGE gene were expressed, with positive expression
rates of 28.6% (2/7) and 14.3% (1/7), respectively. The
positive rates of MAGE-1 and MAGE-3 genes in serous
adenocarcinoma were significantly higher than that in
other types of ovarian cancer (P < 0.05).
Further statistical analyses of MAGE, GAGE and BAGE
gene expression, as well as the clinical data from 41 cases
of ovarian cancer were further conducted. Our results
demonstrated that gene expression was not correlated
with menopause or lymph node metastasis, and MAGE-1
and MAGE-3 gene expression was closely related to cell
differentiation and cancer clinical stage (P < 0.05). The
lower the histological grade, the later the clinical stage,
and the higher the expression rates of MAGE-1 and
MAGE-3 genes. Therefore, MAGE-1 and MAGE-3 genes
were closely related to the degree of malignancy and
prognosis of the ovarian cancer; thus, the two could be
used as independent prognostic indicators for ovarian
cancer. The positive rate of BAGE was higher in ovarian
cancer patients with ascites (P < 0.05), which was consis-
tent with the finding of Hofmann et al. [3] that BAGE
mRNA was positively expressed in 56% of ovarian cancer
patients with ascites. These data suggested that BAGE
may be associated with the formation and development
of ascites. In addition, MAGE, GAGE and BAGE genes
were expressed in ovarian cancer cell lines SKOV3,
A2780 and COC1, which further demonstrated the role
of these genes in ovarian cancer diagnoses. It was
Table 3: mRNA expression of MAGE, GAGE and BAGE in different pathological types of ovarian cancer [Cases(%)].
Pathological type Cases (n) MAGE-1 MAGE-3 BAGE GAGE-1/2
Serous cystadenocarcinoma 18 14 (77.8) 12 (66.7) 4 (22.2) 6 (33.3)
Mucinous 
cystadenocarcinoma
13 5 (38.5) 2 (15.4) 1 (7.7) 3 (23)
Endometrial carcinoma 6 2 (33.3) 1 (16.6) 0 (0) 1 (16.7)
Clear cell tumors 4 1 (25) 0 (0) 1 (25) 1 (25)
Table 4: The relationship between pathological features of ovarian cancer and the positive expression rate of MAGE, GAGE 
and BAGE [Cases(%)].
Pathological parameters Cases (n) MAGE-1 MAGE-3 BAGE GAGE-1/2
Age
Pre-menopausal 26 16 (61.5) 9 (34.6) 4 (15.4) 7(26.9)
Post-menopausal 15 6 (40) 6 (40) 2 (13.3) 4 (26.7)
Histological grade
G1 ~G2 24 16 (66.7) 12(50) 3 (12.5) 6(25)
G3 17 6 (35.3) 3(17.6) 3(17.6) 5 (29.4)
Clinical stage
I ~II 14 4(28.6) 2 (14.3) 2 (14.3) 4 (28.6)
III ~IV 27 18 (66.7) 13 (48.1) 4 (14.8) 7 (25.9)
Lymph node metastasis
With 15 10 (66.7) 8 (53.3) 3 (20) 5 (33.3)
Without 26 12 (46.2) 7 (26.9) 3(11.5) 6 (23.1)
Ascites
With 15 10 (66.7) 8 (53.3) 5 (33.3) 7 (46.7)
Without 26 12 (46.2) 7 (26.9) 1 (3.8) 4 (15.4)Zhang et al. BMC Cancer 2010, 10:163
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reported that the vaccine manufactured by using MAGE
gene products had an acceptable toxicity and displayed a
good effect on tumor response in the absence of other
therapy [7]. The MAGE-3 gene has been used as a reliable
indicator to detect melanoma cells in peripheral blood in
the Gene Chip studies, as well as to monitor the infiltra-
tive growth of tumor cells, thus, allowing for the determi-
nation of appropriate treatment interventions [8].
The products of the MAGE, BAGE and GAGE family
genes are tumor-specific antigens that are highly
expressed in different histological types of tumors.
Therefore, these genes have drawn much attention for
tumor immunotherapy. Currently, the most common
application of MAGE, BAGE and GAGE genes in the
ovarian cancer vaccine is the peptide vaccine and DC
vaccine [9]. Although recent studies of these genes, espe-
cially the MAGE genes, have been conducted by domestic
and international scholars and have resulted in new
insight into these genes, our understanding of these genes
is still insufficient. Due to the heterogeneity of tumor
cells, the expression of MAGE, BAGE and GAGE family
members may be varied in different types of ovarian
tumors or in different parts of the same tumor, and it is
very difficult to choose a target antigen for immunother-
apy [10]. Through the present work, we believe that the
question of whether MAGE, BAGE and GAGE genes
could be useful as molecular markers and tumor-specific
immunotherapy target sites for ovarian cancer still
requires more in-depth investigation.
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